When Do We Decide That Generic and Brand-Name Drugs Are Clinically Equivalent? Perfecting Decisions With Imperfect Evidence

Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10):e004158. doi: 10.1161/CIRCOUTCOMES.117.004158.

Author

David A Alter¹

Affiliation

¹ From the University Health Network-Toronto Rehabilitation Institute (UHN-TRI), ON, Canada; and Department of Medicine, Institute for Clinical Evaluative Sciences (ICES), University of Toronto, ON, Canada. dalter@ices.on.ca.

PMID: 28974513
DOI: 10.1161/CIRCOUTCOMES.117.004158

No abstract available

Keywords: Editorials; candesartan; drug substitution; hospitalization; losartan; valsartan.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Angiotensin Receptor Antagonists*
Canada
Drug Costs
Drugs, Generic*
Humans
Quebec

Substances

Angiotensin Receptor Antagonists
Drugs, Generic